Following a re-submission:
clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) is accepted for restricted use within NHS Scotland.
Indication under review: for focal spasticity, including the treatment of arm symptoms associated with focal spasticity in conjunction with physiotherapy.
SMC restriction: for focal spasticity of the upper limbs associated with stroke.
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) produces a localised reduction in muscle tone in patients with post-stroke upper limb spasticity and can improve patient disability at 16 weeks. It continues to be effective after repeated administrations with no new adverse events apparent.
Download detailed advice141KB (PDF)
Medicine details
- Medicine name:
- clostridium botulinum toxin A (Dysport)
- SMC ID:
- 353/07
- Indication:
- For the treatment of focal spasticity, including arm symptoms associated with focal spasticity, in conjunction with physiotherapy.
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 14 January 2013
The use of botulinum toxin type A in upper limb spasticity has become established according to local protocols. An extension to the licensed indication for an alternative botulinum toxin type A-containing medicine to remove the limitation to patients post stoke will not be assessed by SMC. Consequently, no SMC advice will be issued for the use of botulinum toxin type A (Dysport) in the full licensed indication “focal spasticity of upper limbs in adults”. Use of botulinum toxin type A in upper limb spasticity should be in line with local formulary decisions.